USPTO serial 78420082
HIT
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- BROWN, BARBARA TROFFKIN
- Law office
- TMO LAW OFFICE 116
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with HIT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John J. O'Malley
JOHN J O'MALLEY VOLPE & KOENIG PC30 S 17TH ST STE 1600UNITED PLZPHILADELPHIA, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations adapted for the topical, injectable, and intravenous treatment of the following, cancer, increasing activity of macrophages; reduction of swelling in the brain of person suffering brain trauma; herpes, canker sores, shingles; renal failure, cardiac insufficiency, hypertension, oedema; infection, acne, mononucleosis; transplants; inflammation, elimination of tumor breakdown material (toxins and debris), decreasing side effects, relief of pain; detoxification, brochodilation; vascular ischemia; HIV(AIDS); diabetes; post-menopause; prevention of topical infection; reduction of swelling; hypertension, cardiac insufficiency; prostaglandin synthesis inhibition; enhancement of oxygenation of tissue by perfusion fluid bathing of the tissue (for transplantation purposes); sub-retinal neovascularization and as an adjunct to the treatment of cancer to prevent metastasis; arthritis or pannus; cancer tumors; inhibiting angiogenesis; controlling angiogenesis; regressing angiogenesis; basal cell carcinoma; actinic keratoses; liver spots; squamous cell tumors; metastatic cancer of the breast to the skin; primary and metastatic melanoma of the skin; malignancies and/or tumor of the skin; genital warts (condyloma acuminata); cervical cancer; human papilloma virus (HVP); psoriasis, corns on the feet; and hair loss on the heads of pregnant women; topical treatment of pain in the skin and or exposed tissue; clearing of atherosclerosis; prevention of arterial restenosis after balloon angioplasty; macrophage infiltration; pharmaceutical preparations comprising hyaluronan; licensing of intellectual property technology and research and developing for others, regarding pharmaceutical preparations, including pharmaceutical preparations comprising hyaluronan, adapted for the topical, injectable, and intravenous treatment of medical conditions and disease in humans | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 8, 2005 | MAB1 | ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT | — |
| Jul 7, 2005 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Jul 5, 2005 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Jan 3, 2005 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 3, 2005 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 15, 2004 | DOCK | ASSIGNED TO EXAMINER | — |
| May 24, 2004 | NWAP | NEW APPLICATION ENTERED | — |